Botulax 200U Botulinum Toxin

Botulax 200U is a new generation of Botulinum Toxin Type A product that boasts high purity and superior effectiveness.

It is made using over a dozen purification processes such as sterilization, impurity removal, nucleic acid removal, heat removal, enzymatic hydrolysis, isoelectric point, salting out, dialysis, ultrafiltration, column chromatography, and repeated recrystallization, resulting in a pure and effective protein without any impurities.

The product is easy to dissolve and results in a clear and transparent solution after dissolution. Botulax is certified by the Korean KDA and GMP.

Botulax is formulated with good product stability, which is unique and has a good protective effect on the product. After control experiments, the stability of Botulax was found to be the best among similar products worldwide, and even after being stored at room temperature for over a week, the activity remained basically unchanged.

Botulax is safe and does not produce allergic reactions. There is no risk of viruses in blood products, and it does not have the disadvantage of macromolecular animal proteins being prone to allergic reactions. It is easily absorbed by muscles and has a good nutritional effect on the injection site.

The active ingredient in Botulax is Clostridium Botulinum Toxin Type A (Strain: Clostridium botulinum CBFC26), with a dose of 200 units (U).

Botulax should be stored sealed and at 2-8°C. The expiry date is 36 months from the date of manufacture. The product is packaged in vials and is a white injectable dry powder in a transparent glass vial which should become a colorless, transparent liquid when reconstituted with a solvent (normal saline solution).

Botulax is intended for the treatment of benign essential blepharospasm in adults over 18 years of age, temporary improvement of moderate to severe glabellar lines that form as a result of corrugator muscles and/or procerus muscle activity in adults aged between 18 and 65, treatment of post-stroke upper-limb spasticity and treatment for pediatric cerebral palsy patient aged 2 or above with dynamic equinus foot deformity by spasticity.